About
David Grainger, a former Cambridge academic and Nature/Science-published scientist, co-founds asset‑centric single‑program biotechs, combines R&D leadership with operational experience, and writes on pharma R&D and deals for DrugBaron and Forbes.
Invests in
BiotechDeep TechDigital HealthHealthtechMedical Devices
Investments
Led
Padlock TherapeuticsXO1
Board seats
Morphogen-IXRivus PharmaceuticalsZ-Factor
Per the firm's website.
Colleagues at Medicxi
Frequently asked questions
- Who is David Grainger?
- David Grainger, a former Cambridge academic and Nature/Science-published scientist, co-founds asset‑centric single‑program biotechs, combines R&D leadership with operational experience, and writes on pharma R&D and deals for DrugBaron and Forbes.
- Where does David Grainger work?
- David Grainger is Co-founder and Venture Partner at Medicxi.
- What does David Grainger invest in?
- David Grainger invests in Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- What boards does David Grainger sit on?
- David Grainger holds tracked board seats at Morphogen-IX, Rivus Pharmaceuticals, Z-Factor.
- What companies has David Grainger invested in?
- Investments tracked here include Padlock Therapeutics, XO1.
- Does David Grainger lead rounds?
- Yes — David Grainger has led 2 tracked investments.